Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Factors Associated With the Discussion of Fertility Preservation in a Cohort of 1,357 Young Breast Cancer Patients Receiving Chemotherapy.
Hours A, Toussaint A, De Castelbajac V, Sautter C, Borghese J, Frank S, Coussy F, Laas E, Grandal B, Dumas E, Daoud E, Guerin J, Balezeau T, Feron JG, Fourchotte V, Kirova Y, Lerebours F, Pierga JY, Guillot E, Santulli P, Grynberg M, Sonigo C, Reyrat E, Soibinet-Oudot P, Reyal F, Hamy AS. Hours A, et al. Among authors: lerebours f. Front Oncol. 2021 Sep 28;11:701620. doi: 10.3389/fonc.2021.701620. eCollection 2021. Front Oncol. 2021. PMID: 34650912 Free PMC article.
[Rectal toxicity of Veganine suppositories: an unusual presentation].
Legallicier B, Parent B, Chamoun S, Duparc F, Lemoine F, Lerebours F, Colin R. Legallicier B, et al. Among authors: lerebours f. Gastroenterol Clin Biol. 1991;15(1):92-3. Gastroenterol Clin Biol. 1991. PMID: 2010078 French. No abstract available.
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.
Pierga JY, Petit T, Delozier T, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, Charafe-Jauffret E, Pavlyuk M, Kraemer S, Bidard FC, Viens P. Pierga JY, et al. Among authors: lerebours f. Lancet Oncol. 2012 Apr;13(4):375-84. doi: 10.1016/S1470-2045(12)70049-9. Epub 2012 Feb 28. Lancet Oncol. 2012. PMID: 22377126 Clinical Trial.
Non-sentinel lymph node metastasis prediction in breast cancer with metastatic sentinel lymph node: impact of molecular subtypes classification.
Reyal F, Belichard C, Rouzier R, de Gournay E, Senechal C, Bidard FC, Pierga JY, Cottu P, Lerebours F, Kirova Y, Feron JG, Fourchotte V, Vincent-Salomon A, Guinebretiere JM, Sigal-Zafrani B, Sastre-Garau X, De Rycke Y, Coutant C. Reyal F, et al. Among authors: lerebours f. PLoS One. 2012;7(10):e47390. doi: 10.1371/journal.pone.0047390. Epub 2012 Oct 9. PLoS One. 2012. PMID: 23056641 Free PMC article.
Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data.
Pierga JY, Petit T, Lévy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, Charafe-Jauffret E, Bonneterre J, Hernandez J, Bidard FC, Viens P. Pierga JY, et al. Among authors: lerebours f. Clin Cancer Res. 2015 Mar 15;21(6):1298-304. doi: 10.1158/1078-0432.CCR-14-1705. Epub 2014 Dec 23. Clin Cancer Res. 2015. PMID: 25538259 Clinical Trial.
152 results